AI assistant
Sending…
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
Jan 4, 2012
29977_dirs_2012-01-04_8fdd5b2e-1a41-40ed-92b2-136b618a8306.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-01-03
Reporting Person: SING GEORGE L (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-01-03 | Non-Qualified Stock Option (right to buy) | $57.11 | A | 15000 | Acquired | 2022-01-03 | Common Stock (15000) | Direct |
Footnotes
F1: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant
F2: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
More from REGENERON PHARMACEUTICALS, INC.
Regulatory Filings
2026
May 8
Major Shareholding Notification
2026
Apr 30
Interim / Quarterly Report
2026
Apr 29
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Proxy Solicitation & Information Statement
2026
Apr 24
Regulatory Filings
2026
Apr 8
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3